Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052679 | 1.00 | GRIK1 (0.43) | GRIK1GRIK2L3MBTL1CPA1USP2 | |
| SCHEMBL2189967 | 1.00 | GRIK1 (0.43) | GRIK1GRIK2L3MBTL1CPA1USP2 | |
| SCHEMBL9709605 | 0.83 | GRIK1 (0.41) | GRIK1GRIK2L3MBTL1CPA1USP2 | |
| SCHEMBL7473152 | 0.83 | L3MBTL1 (0.46) | L3MBTL1USP2KMT2AHDAC3HDAC1 | |
| SCHEMBL4839844 | 0.83 | MEN1 (0.47) | MEN1GAAKMT2AHDAC3HDAC1 | |
| SCHEMBL23771465 | 0.81 | CTSK (0.49) | GRIK1GRIK2L3MBTL1USP2MEN1 | |
| SCHEMBL26645765 | 0.81 | CTSK (0.49) | GRIK1GRIK2L3MBTL1USP2MEN1 | |
| SCHEMBL15684081 | 0.81 | L3MBTL1 (0.44) | GRIK1GRIK2L3MBTL1USP2HDAC3 | |
| SCHEMBL12200990 | 0.80 | ALDH1A1 (0.41) | GRIK1GRIK2L3MBTL1USP2MEN1 | |
| SCHEMBL19712820 | 0.80 | GRIK1 (0.50) | GRIK1GRIK2CPA1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-3887365-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| CN-113166101-A | Cyclic pentameric compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166114-A | Cyclic tetramer compounds as proprotein convertase subtilisin/KEXIN 9 type (PCSK9) inhibitors for the treatment of metabolic disorders | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| WO-2020110009-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |
| US-20200164024-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-05-28 | — | — | US | disclosed |
| EP-2897960-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS NOTCH INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-03 | — | — | EP | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| EP-0944587-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2002-03-20 | — | — | EP | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0944587-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-29 | — | — | EP | disclosed |
| US-5773428-A | BONE DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1998024759-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| EP-0807114-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996023791-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | GRIK1 2666/4885GRIK2 4214/4885L3MBTL1 2963/4885 |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | GRIK1 2666/4885GRIK2 4214/4885L3MBTL1 2963/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | GRIK1 2666/4885GRIK2 4214/4885L3MBTL1 2963/4885 |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | GRIK1 2943/4885GRIK2 4066/4885L3MBTL1 1682/4885 |
| US-20200164024-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | GRIK1 2666/4885GRIK2 4214/4885L3MBTL1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.